The In Vivo Revolution: Can We Deliver on the Promise of In Vivo Cell Therapy?

Session details:

As early clinical data begin to emerge, what scientific, clinical, and operational hurdles must still be overcome before in vivo approaches can achieve broad clinical impact? Discussion Points

• What are the biggest unresolved challenges facing in vivo cell therapy?
• Which delivery platforms are showing the greatest promise?
• Can in vivo approaches achieve the durability and potency needed for long-term clinical benefit?
• How can safety, lymphodepletion, and repeat dosing be optimized to enable broader use?
• What are early clinical data teaching us about persistence, relapse, and retreatment?
• Where is in vivo cell therapy most likely to demonstrate meaningful clinical impact first?